Korro Bio

KRROPhase 2

Korro Bio is developing transformative genetic medicines by co-opting the body's natural RNA editing machinery to correct disease-causing mutations or modulate protein function. The company's OPERA® platform and first-generation CHORD™ oligonucleotides are designed for high specificity, transient activity, and delivery via clinically validated methods like GalNAc. With a pipeline focused on liver and CNS diseases, Korro is advancing multiple wholly-owned programs, recently securing an $85 million private placement to fund its development efforts.

Market Cap

$106.6M

Focus

RNA & Gene Therapy

KRRO · Stock Price

USD 10.7597.75 (-90.09%)

Historical price data

AI Company Overview

Technology Platform

The OPERA® (Oligonucleotide Promoted Editing of RNA) platform co-opts the endogenous ADAR enzyme using proprietary, chemically modified oligonucleotides to make precise, single-base edits to RNA, enabling the repair of pathogenic mutations or modulation of protein function.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
KRRO-110	Alpha-1 Anti-trypsin Deficiency	Phase 1/2

Opportunities

The OPERA® platform's ability to make precise RNA edits offers a vast opportunity to treat both rare genetic diseases (through mutation repair) and highly prevalent conditions (through pathway modulation).

Success with lead liver-targeted programs could validate the platform for expansion into other tissues, particularly the central nervous system, where Korro already has an active ALS program.

Risk Factors

Key risks include the unproven clinical safety and efficacy of the novel RNA editing modality, undefined regulatory pathways, significant competition from established genetic medicine companies, and the inherent financial and execution risks of a preclinical-stage biotech dependent on capital markets.

Competitive Landscape

Korro competes with DNA editing (CRISPR) companies, where it differentiates on safety and reversibility, and with RNA-targeting (ASO/siRNA) companies, where it differentiates by editing rather than knocking down RNA. It also faces competition from other emerging RNA editing biotechs, competing on the specifics of its oligonucleotide design, delivery, and platform efficiency.